Primary Aldosteronism: State-of-the-Art Review.

Am J Hypertens

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Published: December 2022

We are witnessing a revolution in our understanding of primary aldosteronism (PA). In the past 2 decades, we have learned that PA is a highly prevalent syndrome that is largely attributable to pathogenic somatic mutations, that contributes to cardiovascular, metabolic, and kidney disease, and that when recognized, can be adequately treated with widely available mineralocorticoid receptor antagonists and/or surgical adrenalectomy. Unfortunately, PA is rarely diagnosed, or adequately treated, mainly because of a lack of awareness and education. Most clinicians still possess an outdated understanding of PA; from primary care physicians to hypertension specialists, there is an urgent need to redefine and reintroduce PA to clinicians with a modern and practical approach. In this state-of-the-art review, we provide readers with the most updated knowledge on the pathogenesis, prevalence, diagnosis, and treatment of PA. In particular, we underscore the public health importance of promptly recognizing and treating PA and provide pragmatic solutions to modify clinical practices to achieve this.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729786PMC
http://dx.doi.org/10.1093/ajh/hpac079DOI Listing

Publication Analysis

Top Keywords

primary aldosteronism
8
state-of-the-art review
8
understanding primary
8
adequately treated
8
aldosteronism state-of-the-art
4
review witnessing
4
witnessing revolution
4
revolution understanding
4
aldosteronism decades
4
decades learned
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!